- Home
- GRVY vs SCTX Comparison
GRVY vs SCTX Comparison
Compare GRVY & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRVY | SCTX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.7M | 536.5M |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GRVY | SCTX |
|---|---|---|
| Price | $67.40 | $17.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 13.0K | ★ 375.5K |
| Earning Date | 11-06-2026 | 09-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.54 | $13.50 |
| 52 Week High | $76.00 | $39.60 |
Technical Indicators
Market Signals| Indicator | GRVY | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 35.39 |
| Support Level | $60.04 | N/A |
| Resistance Level | $71.94 | $26.50 |
| Average True Range (ATR) | 1.59 | 3.67 |
| MACD | -0.23 | -1.22 |
| Stochastic Oscillator | 27.27 | 18.79 |
Price Performance
Historical ComparisonAbout GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. The gaming products of the company include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation. Geographically, it derives maximum revenue from Taiwan.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.